The latest skirmish in the battle between human and microbe played out on Nov. 29 in a hotel conference room in Silver Spring, Md., where, an assembly of scientists and clinicians debated the merits of an experimental antibiotic. For some, the coveted prize was not just an endorsement of the drug itself, but a sign that the Food and Drug Administration is finally ready to rethink its clinical-trial requirements for antibiotics—requirements that the drug industry says are unrealistic.
FDA under pressure to relax drug rules
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.